Showing 541-550 of 650 results for "".
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- Glenmark Pharmaceuticals Enters US Branded Dermatology Segmenthttps://practicaldermatology.com/news/glenmark-pharmaceuticals-enters-us-branded-dermatology-segment/2457537/Glenmark Pharmaceuticals is entering into the branded dermatology segment in the United States. The branded portfolio for the US market will be developed and commercialized by Glenmark Therapeutics Inc., USA, a wholly owned subsidiary of Glenmark Holding, SA. This represents an imp
- New Acoustic Shockwave Technology May Speed Laser Tattoo Removalhttps://practicaldermatology.com/news/new-acoustic-shockwave-technology-may-speed-laser-tattoo-removal/2457548/Soliton, Inc. is introducing new acoustic shockwave technology for quicker laser tattoo removal. What’s more, the new device also shows potential in aesthetics market for cellulite and fat removal. The patented
- Sinclair Pharma Announces Leadership Changeshttps://practicaldermatology.com/news/sinclair-pharma-announces-leadership-changes/2457491/Sinclair Pharma Limited reported that effective at the end of the year, Doug Abel has resigned his position as Head of North America and President of Silhouette Lift, Inc., to lead a new aesthetic venture and has licensed the US sales and marketing rights to the Refine Support System from Sinclai
- Amgevita, Amgen's Biosimilar Adalimumab, Launches in Europehttps://practicaldermatology.com/news/amgevita-amgens-biosimilar-adalimumab-launches-in-europe/2457555/Amgen's Amgevita, a biosimilar to adalimumab, has launched in markets across Europe. Amgevita is the first adalimumab biosimilar to be approved by the European Commission (EC) and is authorized for the treatment of inflammatory diseases in adults, including moder
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is
- Business News: Candela Acquires Ellipsehttps://practicaldermatology.com/news/business-news-candela-acquires-ellipse/2457616/Candela Corporation has acquired Ellipse, a Danish medical device company that manufactures and markets Intense Pulsed Light (IPL) and laser-based platforms for a wide variety of medical and aesthetic skin treatments. Financial terms of the agreement were not disclosed. “The
- Demand for Vegan Cosmetics Expected to Soarhttps://practicaldermatology.com/news/demand-for-vegan-cosmetics-to-soar-bi-2025/2457631/The global vegan cosmetics market size is projected to reach $20.8 billion by 2025, progressing at a Compound Annual Growth Rate (CAGR) of 6.3 percent during the forecast period. Spiraling demand for vegan cosmetics among millennials is one of the primary growth stimulants of the market,
- Novartis Enters Licensing Deal for IL-17C Compound for Atopic Dermatitishttps://practicaldermatology.com/news/novartis-enters-licensing-deal-for-il-17c-compound-for-atopic-dermatitis/2457689/Novartis has entered into an exclusive license agreement with biotech companies Galapagos NV, Mechelen (Belgium) and MorphoSys AG, Planegg/Munich (Germany) to acquire the exclusive global development and marketing rights to MOR106 for atopic dermatitis and all other potential indications. Novarti
- Sensus Healthcare Forms Strategic Agreement with SkinCure Oncologyhttps://practicaldermatology.com/news/sensus-healthcare-forms-strategic-agreement-with-skincure-oncology/2457697/Sensus Healthcare, Inc., which specializes in the non-invasive treatment of non-melanoma skin cancers (NMSC) and keloids with Image-Guided Superficial Radiation Therapy (IGSRT), formed a strategic agreement focused on marketing the SRT-100 Vision with SkinCure Oncology, a leading turnkey provider